Sodium–glucose co-transporter 2 (SGLT2) inhibitors offer cardiovascular benefits in patients with heart failure, yet their direct effects on myocardial fibrosis—particularly in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D)—remain underexplored. The gene discussed is SLC5A2; the disease is Myocardial fibrosis.